131 related articles for article (PubMed ID: 25497908)
21. Dose matters: the importance of appropriate dosing: a case report on sunitinib treatment in a patient with metastatic renal cell carcinoma.
Bojic M; Schmidinger M
Clin Genitourin Cancer; 2012 Dec; 10(4):277-9. PubMed ID: 22658385
[No Abstract] [Full Text] [Related]
22. Intermittent sunitinib for metastatic renal cell carcinoma.
Venkatesan P
Lancet Oncol; 2017 Mar; 18(3):e139. PubMed ID: 28163004
[No Abstract] [Full Text] [Related]
23. When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report.
Sbitti Y; Debbagh A; Slimani K; Mahi M; Errihani H; Ichou M
J Med Case Rep; 2018 Mar; 12(1):80. PubMed ID: 29554941
[TBL] [Abstract][Full Text] [Related]
24. Intermittent treatment with sunitinib may achieve complete response in metastatic renal cell carcinoma.
Aksu G; Ensaroglu F; Dolasik I; Temiz S; Halis H; Sener SY; Kaya A; Uygun K
J BUON; 2010; 15(4):798-9. PubMed ID: 21229650
[No Abstract] [Full Text] [Related]
25. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
Park CY
Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356
[TBL] [Abstract][Full Text] [Related]
26. Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma.
De Vincenzo F; Zucali PA; Ceresoli GL; Colombo P; Simonelli M; Lorenzi E; Perrino M; Gianoncelli L; De Sanctis R; Graziotti P; Santoro A
J Clin Oncol; 2011 Jun; 29(18):e529-31. PubMed ID: 21483010
[No Abstract] [Full Text] [Related]
27. Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.
Liu G; Jeraj R; Vanderhoek M; Perlman S; Kolesar J; Harrison M; Simoncic U; Eickhoff J; Carmichael L; Chao B; Marnocha R; Ivy P; Wilding G
Clin Cancer Res; 2011 Dec; 17(24):7634-44. PubMed ID: 22038997
[TBL] [Abstract][Full Text] [Related]
28. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
[TBL] [Abstract][Full Text] [Related]
29. Sunitinib re-challenge in metastatic renal cell carcinoma treated sequentially with tyrosine kinase inhibitors and everolimus.
Paule B; Brion N
Anticancer Res; 2011 Oct; 31(10):3507-10. PubMed ID: 21965770
[TBL] [Abstract][Full Text] [Related]
30. [Monitoring of metastatic renal cell carcinoma--standards and challenges].
Jäger E
Onkologie; 2010; 33 Suppl 1():15-7. PubMed ID: 20164672
[TBL] [Abstract][Full Text] [Related]
31. Targeted therapy for patients with renal-cell carcinoma.
Rini BI
Lancet Oncol; 2011 Nov; 12(12):1085-7. PubMed ID: 22015058
[No Abstract] [Full Text] [Related]
32. [News on ASCO 2007. Sunitinib in the treatment of metastatic renal carcinoma and gastrointestinal stromal tumors].
Mansueto G; Longo F
Tumori; 2007; 93(5):Suppl 1-16. PubMed ID: 18038894
[No Abstract] [Full Text] [Related]
33. Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC.
Grünwald V; Weikert S; Seidel C; Busch J; Johannsen A; Fenner M; Reuter C; Ganser A; Johannsen M
Onkologie; 2011; 34(6):310-4. PubMed ID: 21625184
[TBL] [Abstract][Full Text] [Related]
34. Results of the first trial assessing adjuvant tyrosine kinase inhibitors in renal cell carcinoma do not reASSURE.
Ouzaid I; Bensalah K
Eur Urol; 2015 Sep; 68(3):542-3. PubMed ID: 26001611
[No Abstract] [Full Text] [Related]
35. [Efficacy of Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma : A Case Report].
Yoshinaga A; Kamata S
Hinyokika Kiyo; 2015 May; 61(5):201-5. PubMed ID: 26087822
[TBL] [Abstract][Full Text] [Related]
36. Alternative sunitinib schedules in metastatic renal cell carcinoma and the RAINBOW study.
Bracarda S;
Ann Oncol; 2015 Jul; 26(7):1512-3. PubMed ID: 25846555
[No Abstract] [Full Text] [Related]
37. First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES.
Schmidinger M; Wittes J
Curr Opin Urol; 2015 Sep; 25(5):395-401. PubMed ID: 26148069
[TBL] [Abstract][Full Text] [Related]
38. Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061).
Abdelraouf F; Smit E; Hasan B; Menis J; Popat S; van Meerbeeck JP; Surmont VF; Baas P; O'Brien M
Eur J Cancer; 2016 Feb; 54():35-39. PubMed ID: 26716400
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature.
Daste A; Gross-Goupil M; Quivy A; François L; Bernhard JC; Ravaud A
Clin Genitourin Cancer; 2016 Oct; 14(5):e525-e527. PubMed ID: 27185091
[No Abstract] [Full Text] [Related]
40. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.
Albiges L; Oudard S; Negrier S; Caty A; Gravis G; Joly F; Duclos B; Geoffrois L; Rolland F; Guillot A; Laguerre B; Legouffe E; Kohser F; Dietrich PY; Theodore CA; Escudier B
J Clin Oncol; 2012 Feb; 30(5):482-7. PubMed ID: 22231040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
